This article was downloaded by:


On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK

41 Mortiller Street, London W 11 SJ11, OF



### Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <a href="http://www.informaworld.com/smpp/title~content=t713597286">http://www.informaworld.com/smpp/title~content=t713597286</a>

# Synthesis of Nucleosides Having Unusual Branched Sugars as Potential Antiviral Agents

Kuniki Kato<sup>a</sup>; Shosuke Yamamura<sup>b</sup>

<sup>a</sup> Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co. Ltd., Tokyo, Japan <sup>b</sup> Department of Chemistry, Faculty of Science and Technology, Keio University, Yokohama, Japan

**To cite this Article** Kato, Kuniki and Yamamura, Shosuke(1999) 'Synthesis of Nucleosides Having Unusual Branched Sugars as Potential Antiviral Agents', Nucleosides, Nucleotides and Nucleic Acids, 18: 4, 657 — 658

To link to this Article: DOI: 10.1080/15257779908041532 URL: http://dx.doi.org/10.1080/15257779908041532

#### PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHESIS OF NUCLEOSIDES HAVING UNUSUAL BRANCHED SUGARS AS POTENTIAL ANTIVIRAL AGENTS

Kuniki Kato\*1 and Shosuke Yamamura<sup>2</sup>

- 1: Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co. Ltd., Shimo, Kita-ku, Tokyo 115, Japan
  - 2: Department of Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi, Yokohama 223, Japan

**ABSTRACT:** Enantiomerically pure novel nucleosides having unusual branched sugars were synthesized in a stereospecific manner from a common chiral pool of (S, S)-1,4-bis(benzyloxy)-2,3-epoxybutane and evaluated for antiviral activity.

In the search for effective, selective, and nontoxic antiviral agents, a variety of strategies have been devised to design nucleoside analogs. These strategies have involved several formal modifications of the naturally occurring nucleosides, especially, alternation of the carbohydrate moiety. Since the naturally occurring purine nucleoside analog oxetanocin A and its derivatives have been found to be effective as anti-HIV-1 and antiherpes virus agents,  $^1$  the syntheses of different types of hydroxymethyl-branched nucleosides (the so-called ring-modified oxetanocin A analogs) have been reported. To further evaluate the structure-activity relationship of hydroxymethyl-substituted nucleosides, we have accomplished the synthesis of unusual branched sugars having bishydroxymethyl groups and their nucleosides (i. e. 1, 2, 3, 4, and 5). As shown in Fig. 1, the synthesis of all of the branched sugars was started from (S, S)-1,4-bis(benzyloxy)-2,3-epoxybutane prepared from (+)-diethyl-L-tartrate. $^2$ 

Synthesis of purine and/or pyrimidine nucleosides from the newly synthesized branched sugars was performed according to the general methodology.<sup>3</sup>

The synthesized nucleosides were evaluated *in vitro* against HSV-1 and HSV-2 in Vero cells by a plaque reduction assay and HIV-1 in MT-4 cells by an indirect immunofluorescence assay, respectively (Table 1). Compounds **1-a** and **1-g** were found to demonstrate potent anti-HIV-1 activity at approximately the same level as ddI with EC50 values of 0.37, 0.46, and 0.46 µg/ml, respectively.

In summary, we have developed the synthesis of novel nucleosides having unusual branched sugars as analogs of oxetanocin A. We have identified [(2'S, 3'S)]

bis(hydroxymethyl)azetidin-1-yl] adenine (1-a) and -guanine (1-g) as good inhibitors of HIV-1 replication.

TABLE 1 Antiviral activities against HSV-1, HSV-2, and HIV-1

$EC_{50} \mu g/ml^a$			
Compound	HSV-1	HSV-2	<u>HIV-1</u>
1-a	33.2	34.9	0.37
1-g	5.36	6.32	0.46
1-t	>100	>100	>100
1-c	>100	>100	>100
2-a	>100	>100	>100
2-g	>100	>100	>100
2-t	>100	>100	>100
3-a	>100	>100	>100
3-t	>100	>100	>100
3-с	>100	>100	>100
4-a	>100	>100	>100
4-t	>100	>100	>100
5-a	>100	>100	>100
5-t	>100	>100	>100
ddI	$ND^b$	ND	0.46
AZT	ND	ND	0.0032
acyclovir	0.32	0.39	ND

a: Concentration required to inhibit HSV-1-, HSV-2-, or HIV-1-induced cytopathic effect by 50 %.

#### REFERENCES

- 1. Masuda, A.; Kitagawa, M.; Tanaka, A.; Saito, S.; Shimada, N.; Ikeda, R.; Hoshino, H.; Daikoku, T.; Nishiyama, Y.J. Antibiot., 1993, 46, 1034-1037.
- Nicolaou, K. C.; Papahatjis, D. P.; Claremon, D. A.; Magolda, R. L.; Dolle, R. E. J. Org. Chem., 1985, 50, 1440-1456.
- 3. Formation of pyrimidine ring: Shaw, G.; Warrener, R. N. J. Chem. Soc., 1958, 153-156. Herdewijin, P.; Kerremans, L.; Wigernick, P.; Vandendriessche, F.; VanAerchot, A. Tetrahedron Lett., 1991, 34, 4397-4400. Formation of purine ring: Watson, A. A.J. Org. Chem., 1974, 39, 2911-2916. Glycosidation with silylatednucleic base: Tseng, C. K-H.; Marquez, V. E.; Milne, G. W. A.; Wysocki, R. J. Jr.; Mitsuya, H.; Shirasaki, T.; Driscoll, J. S. J. Med. Chem., 1991, 34, 343-349.

b: Not determined.